Product
Trametinib
Aliases
GSK1120212, GSK 1120212, GSK-1120212, JTP-74057, MEK Inhibitor GSK1120212 (10 other aliases)
Name
Mekinist
FDA Approved
Yes
103 clinical trials
1 organization
1 drug
2 abstracts
173 indications
1 document
Indication
BRAF V600 Colorectal CancerIndication
MelanomaIndication
BRAF V600 MutationIndication
Colorectal CancerIndication
Thyroid CancerIndication
CancerIndication
Pancreatic Ductal AdenocarcinomaIndication
Advanced Solid TumorIndication
Metastatic Solid TumorIndication
Colorectal cancerIndication
Solid TumorsIndication
KRAS MutationIndication
Advanced or Metastatic Solid TumorsIndication
KRAS Mutation-Related TumorsIndication
Multiple MyelomaIndication
AdjuvantIndication
Amyotrophic lateral sclerosisIndication
cancerIndication
Non-Small Cell LungIndication
BRAFIndication
BRAF V600K Mutation PresentIndication
Anaplastic Thyroid CarcinomaIndication
Metastatic Malignant Solid NeoplasmIndication
Malignant Solid NeoplasmIndication
Metastatic Thyroid CancerIndication
Thyroid CarcinomaIndication
Thyroid Gland Follicular CarcinomaIndication
Thyroid Gland Papillary CarcinomaIndication
EGFRIndication
KRAS Gene MutationIndication
MAP2K1 gene mutationIndication
LymphomaIndication
Malignant NeoplasmIndication
Hematopoietic and Lymphoid Cell NeoplasmIndication
Neurofibromatosis 1Indication
Epithelioid HemangioendotheliomaIndication
Brain MetastasesIndication
Rectal CancerIndication
RAS Family Gene MutationIndication
Colon CancerIndication
Stage IIIA Colon CancerIndication
Stage IIIA Rectal CancerIndication
Lung CancerIndication
Stage IV Colon Cancer AJCC v7Indication
Rectal Cancer, Stage IVA (AJCC v7)Indication
Stage IV melanomaIndication
Stage III MelanomaIndication
Neurofibromatosis type 1Indication
PediatricIndication
NeurofibromaIndication
PlexiformIndication
Stomach CancerIndication
MetaplasiaIndication
Metastatic Lung Non-Small Cell CarcinomaIndication
Recurrent Lung Non-Small Cell CarcinomaIndication
Stage III Lung Cancer AJCC v8Indication
Stage IIIA Lung CancerIndication
Stage IIIB Lung CancerIndication
Stage IV Lung CancerIndication
Lung Cancer Stage IVA AJCC v8Indication
melanomaIndication
Pancreatic adenocarcinomaIndication
Adenocarcinoma of the LungIndication
lung cancerIndication
Metastatic Lung CancerIndication
Low-grade gliomaIndication
Central Nervous System GliomaIndication
Lung Cancer Stage IVIndication
Recurrent Lung AdenocarcinomaIndication
Recurrent Lung CancerIndication
Stage IV Non-Small Cell Lung CancerIndication
Pancreatic CancerIndication
Pancreatic Cancer, Stage IIIndication
Stage IIB Pancreatic CancerIndication
Stage III Pancreatic CancerIndication
Unresectable Pancreatic CarcinomaIndication
LeukemiaIndication
Juvenile MyelomonocyticIndication
Advanced CancerIndication
Solid TumorIndication
Haematological MalignancyIndication
Juvenile Myelomonocytic LeukemiaIndication
Juvenile Chronic Myelogenous LeukemiaIndication
CBL SyndromeIndication
Soft Tissue SarcomaIndication
Arteriovenous MalformationsIndication
Bronchial NeoplasmsIndication
Uveal MelanomaIndication
Stage IV Cutaneous MelanomaIndication
Metastatic MelanomaIndication
Stage III Cutaneous Melanoma AJCC v7Indication
AmeloblastomaIndication
BRAF gene mutationIndication
Thyroid Gland Squamous Cell CarcinomaIndication
Stage IIIC Cutaneous Melanoma AJCC v8Indication
Stage IIID Cutaneous Melanoma AJCC v8Indication
EGFR gene amplificationIndication
EGFR gene mutationIndication
ERBB2 Gene AmplificationIndication
ERBB2 MutationIndication
ERBB3 gene mutationIndication
Erbb4 Gene MutationIndication
Mixed Glio-neuronal TumorsIndication
Pleomorphic XanthoastrocytomaIndication
Cutaneous MelanomaIndication
FollicularIndication
Papillary Thyroid CancerIndication
Follicular Thyroid CancerIndication
Hürthle cell tumorIndication
Hürthle Cell Thyroid NeoplasiaIndication
Metastatic CancerIndication
Venous MalformationIndication
Arterial DiseaseIndication
High-Grade GliomaIndication
Acne RosaceaIndication
ErythematotelangiectaticIndication
TumorIndication
NeoplasiaIndication
Anaplastic Thyroid CancerIndication
BRAF Mutation-Related TumorsIndication
Malignant Solid TumorIndication
Digestive Organ NeoplasmsIndication
Borderline Ovarian Serous TumorIndication
Micropapillary Serous CarcinomaIndication
Ovarian Serous AdenocarcinomaIndication
Primary Peritoneal Serous AdenocarcinomaIndication
Low Grade Serous Ovarian AdenocarcinomaIndication
Bile Duct CancerIndication
Biliary Tract NeoplasmsIndication
CholangiocarcinomaIndication
Recurrent Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromeIndication
Acute Myeloid LeukemiaIndication
Chronic Myelomonocytic LeukemiaIndication
NSCLCIndication
ATCIndication
Prostate CancerIndication
Stage IIIA Cutaneous Melanoma AJCC v7Indication
Stage III Lung Non-Small Cell CancerIndication
Stage IIIA Lung Non-Small Cell CancerIndication
Liver MetastasisIndication
NeoplasmIndication
Anaplastic AstrocytomaIndication
NOSIndication
Anaplastic GangliogliomaIndication
Anaplastic Pleomorphic XanthoastrocytomaIndication
GlioblastomaIndication
Malignant GliomaIndication
Grade 3 GliomaDrug
trametinibIndication
Small Intestine AdenocarcinomaIndication
Acute Lymphoblastic LeukemiaIndication
RelapseIndication
Lymphoblastic LymphomaIndication
Gastric CancerClinical trial
A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal CancerStatus: Active (not recruiting), Estimated PCD: 2024-09-20
Clinical trial
A Dose-escalation and Expansion Phase I/IIa Study of XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)Status: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
COMBI-APlus: Open-label, Phase IIIb Study of Dabrafenib in COMBInation With Trametinib in the Adjuvant Treatment of Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes of an Adapted Pyrexia AE-management Algorithm (Plus)Status: Completed, Estimated PCD: 2020-10-05
Clinical trial
A Phase 1/2, First-in-Human Study of DCC-3116 as Monotherapy and in Combination With RAS/MAPK Pathway Inhibitors in Patients With Advanced or Metastatic Solid Tumors With RAS/MAPK Pathway MutationsStatus: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal CancersStatus: Active (not recruiting), Estimated PCD: 2024-03-11
Clinical trial
Managed Access Program (MAP) Cohort Treatment Plan CDRB436B2005CM to Provide Access to Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic MelanomaStatus:
Clinical trial
A Phase I Open-label Dose Escalation Trial of BI 1701963 as Monotherapy and in Combination With Trametinib in Patients With KRAS Mutated Advanced or Metastatic Solid TumoursStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Clinical trial
A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaStatus: Active (not recruiting), Estimated PCD: 2020-08-11
Clinical trial
An Open-label Study to Assess the Safety and Efficacy of Naporafenib (ERAS-254) Administered With Trametinib in Previously Treated Patients With Locally Advanced Unresectable or Metastatic Solid Tumor Malignancies With RAS Q61X MutationsStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Comparative Effectiveness of Different Targeted Therapies for BRAF-mutated Unresectable/Metastatic Melanoma in the United StatesStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase 1b/2 Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Advanced Solid Tumors (TRIDENT-2)Status: Terminated, Estimated PCD: 2023-03-01
Clinical trial
An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2026-10-12
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer (DTC)Status: Recruiting, Estimated PCD: 2027-05-26
Clinical trial
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer TherapiesStatus: Recruiting, Estimated PCD: 2029-08-25
Clinical trial
A Sequential Dose-Escalation, Randomized, Active-Controlled, Multi-Center, Phase 1/2a Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of SNR1611 in Patients With Amyotrophic Lateral SclerosisStatus: Terminated, Estimated PCD: 2023-04-28
Clinical trial
A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and TrametinibStatus: Completed, Estimated PCD: 2021-12-10
Clinical trial
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-04-26
Clinical trial
An Open-Label, Single-arm Study to Evaluate the Safety and Efficacy of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutation-Positive Metastatic Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-11-21
Clinical trial
COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical ResectionStatus: Completed, Estimated PCD: 2017-06-30
Clinical trial
A Phase I Trial of Concurrent Intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF Mutated Anaplastic Thyroid CancerStatus: Recruiting, Estimated PCD: 2025-04-30
Clinical trial
An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2022-12-01
Clinical trial
A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)Status: Recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid CancersStatus: Active (not recruiting), Estimated PCD: 2021-08-25
Clinical trial
Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine (HCQ) for BRAF V600E-mutant or Trametinib and HCQ for BRAF Fusion/Duplication Positive or NF1-associated Recurrent or Progressive Gliomas in Children and Young AdultsStatus: Recruiting, Estimated PCD: 2026-08-30
Clinical trial
Phase I Trial of Phenformin With Patients With Combination BRAF Inhibitor/MEK Inhibitor in Patients With BRAFV600E/K-mutated MelanomaStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Anti-EGFR-Refractory Stage IV Colorectal Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2025-01-31
Clinical trial
MATCH Treatment Subprotocol S2: Phase II Study of Trametinib in Patients With Tumors With GNAQ or GNA11 MutationsStatus: Active (not recruiting), Estimated PCD: 2020-09-01
Clinical trial
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid HemangioendotheliomaStatus: Completed, Estimated PCD: 2023-06-23
Clinical trial
A Phase 1 Study of Trametinib in Combination With Radiation Therapy for Brain MetastasesStatus: Active (not recruiting), Estimated PCD: 2020-07-10
Clinical trial
A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal CancerStatus: Completed, Estimated PCD: 2023-07-14
Clinical trial
Combined MEK Inhibitor Trametinib and RTK Inhibitor Anlotinib Therapy in Non-G12C KRAS-Mutant Non-Small Cell Lung Cancer PatientsStatus: Completed, Estimated PCD: 2023-07-01
Clinical trial
TraMel-WT: A Stratified Dual-stratum Open-label Two-stage Phase 2 Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type MelanomaStatus: Completed, Estimated PCD: 2023-06-30
Clinical trial
MATCH Treatment Subprotocol S1: Phase II Study of Trametinib in Patients With Tumors With NF1 MutationsStatus: Active (not recruiting), Estimated PCD: 2020-06-30
Clinical trial
Treatment of NF1-related Plexiform Neurofibroma With Trametinib; a Single Arm, Open-label Trial With the Goals of Volumetric Partial Remission and Pain ReliefStatus: Active (not recruiting), Estimated PCD: 2024-07-15
Clinical trial
Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor TreatmentStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer - (IM-BATTLE-2 Program)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Phase 1 Study of Trametinib + Ceritinib in Patients With Unresectable MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-10-28
Clinical trial
Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2021-06-19
Clinical trial
Phase Ib Study Evaluating Safety and Tolerability of Combination Trametinib and Ruxolitinib in Patients With Advanced RAS Mutant Colorectal Cancer and Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2023-06-30
Clinical trial
Risk Stratified Treatment for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia: A Phase I/II Non-randomized Study of Trametinib and Azacitidine With or Without Chemotherapy (IND #164058)Status: Recruiting, Estimated PCD: 2028-12-01
Clinical trial
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to ErlotinibStatus: Completed, Estimated PCD: 2020-12-18
Clinical trial
A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway.Status: Active (not recruiting), Estimated PCD: 2027-03-01
Clinical trial
A Phase Ib Trial of Pembrolizumab (MK-3475) and Trametinib Focused on Advanced KRAS Mutant Non-small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2021-01-28
Clinical trial
THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients With Advanced Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-01-18
Clinical trial
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to Determine the Efficacy in Treatment of Advanced Cancers With a Known Molecular ProfileStatus: Recruiting, Estimated PCD: 2026-11-25
Clinical trial
Molecular Profiling of Advanced Soft-tissue Sarcomas. A Phase III StudyStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children With Relapsed or Refractory Juvenile Myelomonocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2023-03-31
Clinical trial
MATCH Treatment Subprotocol R: Phase II Study of Trametinib in Patients With BRAF Fusions, or With NonV600E, Non-V600K BRAF MutationsStatus: Active (not recruiting), Estimated PCD: 2019-03-18
Clinical trial
Pilot Study on the Efficacy of MEK1/MEK2 Inhibitor Trametinib in Patients With Surgical Unruptured Arteriovenous MalformationsStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
An Open-label, Multicenter, Phase I Dose-escalation Trial of EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and Acquired EGFR p.T790M-positive Resistance to 1st or 2nd Generation EGFR TKI Therapy Remark: According to Version V02_0 of the Protocol, Patients May Also be Eligible if EGFR TKI-treatment naïve, EGFR p.T790M-negative at Progression While on EGFR TKI Therapy or After Progression While on Osimertinib TreatmentStatus: Completed, Estimated PCD: 2022-09-30
Clinical trial
Phase I/II Study of BET and MEK Inhibition in Advanced Uveal MelanomaStatus: Withdrawn, Estimated PCD: 2025-07-31
Clinical trial
A Phase I/II Trial of Dabrafenib, Trametinib and Metformin Administered to Unresectable Stage IIIC and Stage IV BRAF V600E + Melanoma PatientsStatus: Withdrawn, Estimated PCD: 2017-11-17
Clinical trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III TrialStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated AmeloblastomaStatus: Completed, Estimated PCD: 2018-11-05
Clinical trial
Pembrolizumab in Combination With Dabrafenib and Trametinib as a Neoadjuvant Strategy Prior to Surgery in BRAF-Mutated Anaplastic Thyroid CancerStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Status: Recruiting, Estimated PCD: 2026-12-20
Clinical trial
Altering Adjuvant Therapy Based on Pathologic Response to Neoadjuvant Dabrafenib and Trametinib (ALTER-PATH NeoDT)Status: Completed, Estimated PCD: 2023-10-09
Clinical trial
A Phase II, Open-label Study of Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene AlterationsStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib, or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"Status: Withdrawn, Estimated PCD: 2023-03-30
Clinical trial
A Randomized and Controlled Phase II Protocol in Non NF1 Pediatric and AYA (Adolescent and Young Adults) Patients Bearing a Newly Diagnosed Low Grade Glioma With Wild Type BRAF Gene Comparing a Daily Oral MEK Inhibitor (Trametinib) Versus Weekly Vinblastine for 18 MonthsStatus: Recruiting, Estimated PCD: 2031-11-01
Clinical trial
A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-01-02
Clinical trial
Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo)Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Efficacy of Immunotherapy in Melanoma Patients With Brain Metastases Treated With SteroidsStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
An Open-label, Pilot Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple MyelomaStatus: Recruiting, Estimated PCD: 2024-09-15
Clinical trial
Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid CancerStatus: Active (not recruiting), Estimated PCD: 2025-09-02
Clinical trial
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant CancerStatus: Active (not recruiting), Estimated PCD: 2018-05-16
Clinical trial
A Phase 1 Study of Nilotinib in Combination With Dabrafenib and Trametinib in BRAF V600 Mutant Metastatic Melanoma After Progression on BRAF/MEK InhibitionStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic MelanomaStatus: Recruiting, Estimated PCD: 2027-07-01
Clinical trial
A Single-center, Phase 1 Dose Escalation Study of Trametinib Combined With HDM201 in Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer.Status: Completed, Estimated PCD: 2023-09-12
Clinical trial
Phase II Clinical Trial of MEK Inhibitor Trametinib in the Treatment of Complicated Extracranial Arterial Venous Malformation (VM)Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
PNOC021: A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients With Recurrent Low-Grade Gliomas and High Grade GliomasStatus: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
PaTcH Trial: A Phase 2 Study to Explore Primary and Emerging Resistance Mechanisms in Patients With Metastatic Refractory Pancreatic Cancer Treated With Trametinib and HydroxychloroquineStatus: Recruiting, Estimated PCD: 2024-07-15
Clinical trial
An Open Label, Single Centre, Phase II Pilot Study of Neoadjuvant Dabrafenib + Trametinib in Patients With Resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 Mutation Positive MelanomaStatus: Active (not recruiting), Estimated PCD: 2017-05-04
Clinical trial
MATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E or V600K Mutations (Excluding Melanoma, Thyroid Cancer, Colorectal Adenocarcinoma, and Non-Small Cell Lung Cancer)Status: Active (not recruiting), Estimated PCD: 2025-04-02
Clinical trial
Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in RosaceaStatus: Completed, Estimated PCD: 2022-12-31
Clinical trial
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular ProfileStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
A Pilot Study of the Addition of Cemiplimab, an Antibody to PD-1, to the Treatment of Subjects With BRAF-Mutant Anaplastic Thyroid Cancer Who Are No Longer Responding to Dabrafenib and TrametinibStatus: Recruiting, Estimated PCD: 2024-06-20
Clinical trial
A Phase 1 Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung CancerStatus: Completed, Estimated PCD: 2022-02-04
Clinical trial
MegaMOST - A Multicenter, Open-label, Biology Driven, Phase II Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations /Characteristics in Advanced / Metastatic Tumors.Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon CancerStatus: Completed, Estimated PCD: 2022-05-05
Clinical trial
A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid CancerStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyStatus: Terminated, Estimated PCD: 2022-12-30
Clinical trial
The BAMM2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced BRAF V600E/K MelanomaStatus: Active (not recruiting), Estimated PCD: 2025-11-30
Clinical trial
Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition: A Single Center Pilot StudyStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2019-04-04
Clinical trial
Phase II Study of Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).Status: Terminated, Estimated PCD: 2022-05-11
Clinical trial
A Phase II Study of Azacitidine, Venetoclax and Trametinib for Patients With Acute Myeloid Leukemia or Higher-Risk Myelodysplastic SyndromeStatus: Completed, Estimated PCD: 2023-02-09
Clinical trial
A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid TumorsStatus: Recruiting, Estimated PCD: 2027-03-11
Clinical trial
Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Single-Arm, Open-Label, Two-Stage Phase II Study of the MEK 1/2 Inhibitor Trametinib in Men With Progressive Metastatic Castrate Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic TherapiesStatus: Active (not recruiting), Estimated PCD: 2019-05-15
Clinical trial
A Phase II Study of the TRIplet Combination of Dabrafenib, Nivolumab, and Trametinib in Patients With Metastatic Melanoma (TRIDeNT) or Binimetinib, EnCorafenib, and NivolumAb (TRIBECA)Status: Active (not recruiting), Estimated PCD: 2024-12-08
Clinical trial
A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-small Cell Lung CancerStatus: Terminated, Estimated PCD: 2017-11-03
Clinical trial
A Phase 1 Trial of Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic DysfunctionStatus: Active (not recruiting), Estimated PCD: 2023-08-04
Clinical trial
Phase 1/2 Study of an EZH2 Inhibitor (Tazemetostat) in Combination With Dual BRAF/MEK Inhibition in Patients With BRAF- Mutated Metastatic Melanoma Who Progressed on Prior BRAF/MEK Inhibitor TherapyStatus: Recruiting, Estimated PCD: 2024-12-04
Clinical trial
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol D: Trametinib + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2029-04-01
Clinical trial
A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer With BRAF V600EmStatus: Not yet recruiting, Estimated PCD: 2030-09-30
Document
DailyMed Label: MekinistOrganization
Novartis Pharmaceuticals Corporation